MRI is an imaging modality that is used in the evaluation and treatment of renal cancer. Although less frequently used than CT, MRI is useful in several aspects of renal cancer evaluation and may have some advantages. MRI has shown promising results for renal cancer staging (especially determination of vascular invasion by tumor), in differentiating malignant from benign complex cystic renal lesions, and in the treatment and follow-up of minimally invasive ablative therapies for renal cancer. In addition, new research shows promise for novel applications of MRI. Herein we review the evolving of MRI in renal cancer imaging.
Get full access to this article
View all access options for this article.
References
1.
JemalA, SiegelR, WardE, MurrayT, XuJ, SmigalC, ThunMJ. Cancer statistics, 2006. CA Cancer J Clin, 2006; 56:106–130.
2.
LipworthL, TaroneRE, McLaughlinJK. The epidemiology of renal cell carcinoma. J Urol, 2006; 176:2353–2358.
3.
MathewA, DevesaSS, FraumeniJFJr., ChowWH. Global increases in kidney cancer incidence, 1973–1992. Eur J Cancer Prev, 2002; 11:171–178.
4.
ChowWH, DevesaSS. Contemporary epidemiology of renal cell cancer. Cancer J, 2008; 14:288–301.
5.
FrankI, BluteML, ChevilleJC, LohseCM, WeaverAL, ZinckeH. Solid renal tumors: An analysis of pathological features related to tumor size. J Urol, 2003; 170:2217–2220.
6.
CollDM, SmithRC. Update on radiological imaging of renal cell carcinoma. BJU Int, 2007; 99:1217–1222.
NikkenJJ, KrestinGP. MRI of the kidney-state of the art. Eur Radiol, 2007; 17:2780–2793.
9.
HoVB, AllenSF, HoodMN, ChoykePL. Renal masses: Quantitative assessment of enhancement with dynamic MR imaging. Radiology, 2002; 224:695–700.
10.
OutwaterEK, BhatiaM, SiegelmanES, BurkeMA, MitchellDG. Lipid in renal clear cell carcinoma: Detection on opposed-phase gradient-echo MR images. Radiology, 1997; 205:103–107.
11.
OlivaMR, GlickmanJN, ZouKH, TeoSY, MorteleKJ, RochaMS, SilvermanSG. Renal cell carcinoma: t1 and t2 signal intensity characteristics of papillary and clear cell types correlated with pathology. AJR Am J Roentgenol, 2009; 192:1524–1530.
12.
GarinJM, MarcoI, SalvaA, SerranoF, BondiaJM, PachecoM. CT and MRI in fat-containing papillary renal cell carcinoma. Br J Radiol, 2007; 80:e193–e195.
13.
SunMR, NgoL, GenegaEM, AtkinsMB, FinnME, RofskyNM, PedrosaI. Renal cell carcinoma: Dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes—Correlation with pathologic findings. Radiology, 2009; 250:793–802.
14.
ErgenFB, HussainHK, CaoiliEMet al.MRI for preoperative staging of renal cell carcinoma using the 1997 TNM classification: Comparison with surgical and pathologic staging. AJR Am J Roentgenol, 2004; 182:217–225.
15.
EisnerBH, FeldmanAS. Nanoparticle imaging for genitourinary cancers. Cancer Biomark, 2009; 5:75–79.
16.
GuimaraesAR, TabatabeiS, DahlD, McDougalWS, WeisslederR, HarisinghaniMG. Pilot study evaluating use of lymphotrophic nanoparticle-enhanced magnetic resonance imaging for assessing lymph nodes in renal cell cancer. Urology, 2008; 71:708–712.
17.
Aslam SohaibSA, TehJ, NargundVH, LumleyJS, HendryWF, ReznekRH. Assessment of tumor invasion of the vena caval wall in renal cell carcinoma cases by magnetic resonance imaging. J Urol, 2002; 167:1271–1275.
18.
HallscheidtPJ, FinkC, HaferkampA, BockM, LuburicA, ZunaI, NoeldgeG, KauffmannG. Preoperative staging of renal cell carcinoma with inferior vena cava thrombus using multidetector CT and MRI: Prospective study with histopathological correlation. J Comput Assist Tomogr, 2005; 29:64–68.
19.
ZiniL, Destrieux-GarnierL, LeroyX, VillersA, HaulonS, LemaitreL, KoussaM. Renal vein ostium wall invasion of renal cell carcinoma with an inferior vena cava tumor thrombus: Prediction by renal and vena caval vein diameters and prognostic significance. J Urol, 2008; 179:450–454; discussion 454.
IsraelGM, HindmanN, BosniakMA. Evaluation of cystic renal masses: Comparison of CT and MR imaging by using the Bosniak classification system. Radiology, 2004; 231:365–371.
22.
O'MalleyRL, GodoyG, HechtEM, StifelmanMD, TanejaSS. Bosniak category IIF designation and surgery for complex renal cysts. J Urol, 2009; 182:1091–1095.
23.
BosniakMA. The current radiological approach to renal cysts. Radiology, 1986; 158:1–10.
24.
McDougalWS, GervaisDA, McGovernFJ, MuellerPR. Long-term followup of patients with renal cell carcinoma treated with radio frequency ablation with curative intent. J Urol, 2005; 174:61–63.
25.
Dominguez-EscrigJL, SahadevanK, JohnsonP. Cryoablation for small renal masses. Adv Urol, 2008; 479495doi:10.1155/2008/479495.
26.
LevinsonAW, SuLM, AgarwalD, SrokaM, JarrettTW, KavoussiLR, SolomonSB. Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol, 2008; 180:499–504discussion 504.
27.
LewinJS, NourSG, ConnellCF, SulmanA, DuerkJL, ResnickMI, HaagaJR. Phase II clinical trial of interactive MR imaging-guided interstitial radiofrequency thermal ablation of primary kidney tumors: Initial experience. Radiology, 2004; 232:835–845.
28.
SvatekRS, SimsR, AndersonJK, Abdel-AzizK, CadedduJA. Magnetic resonance imaging characteristics of renal tumors after radiofrequency ablation. Urology, 2006; 67:508–512.
29.
KawamotoS, PermpongkosolS, BluemkeDA, FishmanEK, SolomonSB. Sequential changes after radiofrequency ablation and cryoablation of renal neoplasms: Role of CT and MR imaging. Radiographics, 2007; 27:343–355.
MogamiT, HaradaJ, KishimotoK, SumidaS. Percutaneous MR-guided cryoablation for malignancies, with a focus on renal cell carcinoma. Int J Clin Oncol, 2007; 12:79–84.
Schor-BardachR, AlsopDC, PedrosaIet al.Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?Radiology, 2009; 251:731–742.
34.
deBazelaire C, AlsopDC, GeorgeD, PedrosaI, WangY, MichaelsonMD, RofskyNM. Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma. Clin Cancer Res, 2008; 14:5548–5554.
35.
GrobnerT. Gadolinium—A specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?Nephrol Dial Transplant, 2006; 21:1104–1108.
